First Light Asset Management’s Nektar Therapeutics NKTR Stock Holding History

First Light Asset Management’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-47,585	Closed	-$25.4M	–	77
2019 Q2	$25.4M	Sell	47,585 -3,309	-7%	-$1.66M	3.53%	8
2019 Q1	$25.6M	Buy	50,894 +2,212	+5%	+$1.31M	3.33%	11
2018 Q4	$24M	Buy	48,682 +23,845	+96%	+$14.4M	3.83%	9
2018 Q3	$22.7M	Sell	24,837 -113	-0.5%	-$96.5K	3.66%	11
2018 Q2	$18.3M	Buy	24,950 +4,944	+25%	+$5.7M	2.85%	14
2018 Q1	$31.9M	Sell	20,006 -3,443	-15%	-$4.44M	7%	2
2017 Q4	$21M	Sell	23,449 -10,097	-30%	-$5.97M	5.76%	2
2017 Q3	$12.1M	Buy	33,546 +2,200	+7%	+$688K	3.82%	8
2017 Q2	$9.19M	Buy	31,346 +16,451	+110%	+$4.75M	3.08%	7
2017 Q1	$5.24M	Buy	+14,895	New	+$3.35M	2%	23

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Light Asset Management's NKTR Position: Q3 2019 in Review

First Light Asset Management sold out of Nektar Therapeutics (NKTR) in Q3 2019, closing a stake of 47,585 shares — an estimated $25.4M sold.

First Light Asset Management first reported a position in NKTR in Q1 2017 and held it in 10 quarters. The position peaked at $31.9M in Q1 2018. 288 funds tracked by Wall St. Rank hold NKTR as of Q3 2019.

First Light Asset Management reported no remaining Nektar Therapeutics position as of Q3 2019 after selling out during the quarter.
First Light Asset Management sold 47,585 Nektar Therapeutics shares in Q3 2019, an estimated $25.4M.
First Light Asset Management first reported a position in Nektar Therapeutics in Q1 2017 and held it in 10 quarters.
First Light Asset Management's Nektar Therapeutics position peaked at $31.9M in Q1 2018.
288 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2019.

Based on First Light Asset Management's 13F filing for Q3 2019, filed 14 Nov 2019.